Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emergency Use Of Unapproved Drugs Outlined In FDA Draft Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA action on requests for consideration will likely take place within hours or days in an emergency situation, according to the draft document. The agency also encourages submission of candidate products prior to an emergency “at the earliest possible time.”

You may also be interested in...



Project BioShield Is Topic Of House Hearings July 12 And 14

Homeland Security/Emergency Preparedness Subcommittee and Government Reform Committee hearings will focus on countermeasure procurement issues and evaluating the effectiveness of the BioShield Act of 2004.

Project BioShield Is Topic Of House Hearings July 12 And 14

Homeland Security/Emergency Preparedness Subcommittee and Government Reform Committee hearings will focus on countermeasure procurement issues and evaluating the effectiveness of the BioShield Act of 2004.

FDA Grants Emergency Use Authorization For Anthrax Vaccine

The ability to opt-out of the inoculation under the Anthrax Vaccine Immunization Program is one condition of FDA’s clearance of Anthrax Vaccine Adsorbed for the prevention of inhalation anthrax. The authorization is the first use of the Emergency Use Authorization under BioShield Act of 2004.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel